The RIQAS Epstein Barr Virus EQA programme is designed to monitor the performance of tests used to detect EBV virus antibodies. All samples are conveniently supplied liquid ready-to-use and are suitable for both quantitative and qualitative methods of analysis.

• Liquid ready-to-use
• 100% human plasma
• Quarterly reporting (3 samples per quarterly distribution)
• Submit results and view reports online via RIQASNet
• Suitable for both quantitative and qualitative methods of analysis

Parameters

• Anti-EBNA IgG
• Anti-EBV VCA IgG
• Anti-EBV VCA IgM